May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Ocular Malignant Melanoma: An Immunohistochemical Profile
Author Affiliations & Notes
  • S. Schneider
    Ophthalmology, University of Cincinnati, Cincinnati, OH, United States
  • H.H. Dimashkieh
    Pathology, University of Cincinnati, Cincinnati, OH, United States
  • G.K. Mutema
    Pathology, University of Cincinnati, Cincinnati, OH, United States
  • H.A. Al-Ahmadie
    Pathology, University of Cincinnati, Cincinnati, OH, United States
  • S. El-Zayaty
    Pathology, University of Cincinnati, Cincinnati, OH, United States
  • J.J. Augsburger
    Pathology, University of Cincinnati, Cincinnati, OH, United States
  • Footnotes
    Commercial Relationships  S. Schneider, None; H.H. Dimashkieh, None; G.K. Mutema, None; H.A. Al-Ahmadie, None; S. El-Zayaty, None; J.J. Augsburger, None.
  • Footnotes
    Support  Research to Prevent Blindness
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 1538. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Schneider, H.H. Dimashkieh, G.K. Mutema, H.A. Al-Ahmadie, S. El-Zayaty, J.J. Augsburger; Ocular Malignant Melanoma: An Immunohistochemical Profile . Invest. Ophthalmol. Vis. Sci. 2003;44(13):1538.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Malignant melanoma of the eye is rare. The majority of ocular melanomas occur in the uveal tract. While uveal melanoma is the most common primary ocular cancer in adults, it has an annual incidence of only 0.7 per 100,000 persons. However, this tumor carries up to a 50% 5-year mortality rate. Because of the rarity of this disease, a large, single institutional study comparing melanoma markers pertaining to the eye has not been reported. Herein, we describe our analysis of key immunohistochemical markers (S-100, HMB-45, MART-1, tyrosinase{TYR}, and microphthalmia transcription factor{Mitf}) of conjunctival, iris, ciliary body, and choroidal malignant melanomas including tumor cell type (spindle, epithelioid, mixed) when appropriate and reactivity patterns. Methods: 52 ocular melanomas (42 ciliochoroidal {CC}, 8 iris {IR}, 2 conjunctival {CONJ}) were studied. The extent of immunohistochemical reactivity was given as a percentage of the tumor size for each marker. The intensity of staining was graded on a 0-3 scale (0= no staining, 1=weak, 2=intermediate, 3=strong) for S-100, HMB-45, MART-1, and TYR, while Mitf nuclear staining was classified as positive (POS) or negative (NEG). Results: The total number of cases staining for each immunohistochemical marker was as follows: S-100 (CC 42/42{100%}, IR 7/8{88%}, CONJ 2/2{100%}), HMB-45 (CC 42/42{100%}, IR 6/8{75%}, CONJ 2/2{100%}), MART-1 (CC 37/42{88%}, IR 7/8{88%}, CONJ 2/2{100%}), TYR (CC 20/42{48%}, IR 3/8{38%}, CONJ 1/2{50%}), Mitf (CC 32/42{76%}, IR 8/8 {100%}, CONJ 2/2{100%}). The average staining intensity of each immunohistochemical marker was as follows: S-100 (CC 1.1, IR 2.4, CONJ 3.0), HMB-45 (CC 2.0, IR 2.0, CONJ 2.5), MART-1 (CC 1.9, IR 2.4, CONJ 2.5), TYR (CC 1.5, IR 2.0, CONJ 3) Conclusions: Similar to dermal melanoma, in general, S-100 and HMB-45 were the most sensitive ocular melanoma markers. MART-1 and Mitf showed comparable sensitivities for all of these ocular tumors and can be useful additions to the melanoma panel. The conjunctival melanomas stained most intensely followed by the iris melanomas for each immunohistochemical marker. The intensity of staining of the ciliochoroidal melanomas was the weakest. In the intraocular group, the epithelioid cell type stained poorly with TYR.

Keywords: immunohistochemistry • melanoma 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×